Kynam Capital reports 5.7% stake in Viridian

Rhea-AI Filing Summary

Kynam Capital Management, LP, its general partner Kynam Capital Management GP, LLC, and Yue Tang report their ownership in Viridian Therapeutics, Inc. common stock on an amended Schedule 13G. The group reports shared voting and dispositive power over 6,453,877 shares, representing 5.7% of the common stock. Each reporting person lists no sole voting or dispositive power and an aggregate amount beneficially owned of 0, while detailing the same shared voting and dispositive position. The securities are Viridian common stock, $0.01 par value, CUSIP 92790C104.

Key Figures

Shared voting power: 6,453,877 shares Shared dispositive power: 6,453,877 shares Ownership percentage: 5.7% +1 more

4 metrics

Shared voting power 6,453,877 shares Shares of Viridian common stock over which the group has shared voting power

Shared dispositive power 6,453,877 shares Shares of Viridian common stock over which the group has shared dispositive power

Ownership percentage 5.7% Percent of Viridian common stock class associated with the reported position

Par value per share $0.01 Par value of Viridian Therapeutics common stock

Key Terms

Schedule 13G/A, beneficially owned, shared voting power, shared dispositive power, +1 more

5 terms

Schedule 13G/A regulatory

"reports their ownership in Viridian Therapeutics, Inc. common stock on an amended Schedule 13G"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: 0"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

shared voting power financial

"Shared Voting Power 6,453,877.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

shared dispositive power financial

"Shared Dispositive Power 6,453,877.00"

percent of class financial

"Percent of class: 5.7 %"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership in Viridian Therapeutics (VRDN) does Kynam Capital report in this Schedule 13G/A?

Kynam Capital Management, its GP, and Yue Tang report shared voting and dispositive power over 6,453,877 shares of Viridian Therapeutics common stock, representing 5.7% of the outstanding class as disclosed in the Schedule 13G/A.

Who are the reporting persons in the Viridian Therapeutics (VRDN) Schedule 13G/A?

The reporting persons are Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang. All three report identical shared voting and dispositive power over 6,453,877 Viridian Therapeutics common shares on this amended Schedule 13G.

What percentage of Viridian Therapeutics (VRDN) shares is reported on this amended Schedule 13G?

The filing reports that the group’s position represents 5.7% of Viridian Therapeutics’ common stock. This percentage is associated with 6,453,877 shares over which the reporting persons have shared voting and shared dispositive power.

Do the reporting persons have sole or shared voting power over Viridian Therapeutics (VRDN) shares?

Each reporting person discloses 0 shares of sole voting power and 6,453,877 shares of shared voting power. They also report 0 shares of sole dispositive power and 6,453,877 shares of shared dispositive power over Viridian common stock.

What class of Viridian Therapeutics (VRDN) securities is covered in this Schedule 13G/A?

The filing covers Common Stock, $0.01 par value, of Viridian Therapeutics, Inc. The securities are identified by CUSIP 92790C104, and the reported holdings relate specifically to this class of common stock.

Where are the issuer and reporting persons based in the Viridian Therapeutics (VRDN) Schedule 13G/A?

Viridian Therapeutics’ principal executive offices are at 221 Crescent Street, Suite 103A, Waltham, MA 02453. The reporting persons list their principal business office at 221 Elm Road, Princeton, New Jersey 08540, with entities formed in Delaware and Yue Tang a U.S. citizen.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 12:18 PM Accepted by SEC EDGAR 08/14/2026 - 12:17 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Viridian Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.01 par value

(Title of Class of Securities)

92790C104

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 92790C104

1

Names of Reporting Persons

Kynam Capital Management, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,453,877.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,453,877.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.7 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP Number(s): 92790C104

1

Names of Reporting Persons

Kynam Capital Management GP, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,453,877.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,453,877.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.7 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 92790C104

1

Names of Reporting Persons

Yue Tang

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 6,453,877.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 6,453,877.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.7 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Viridian Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 221 Crescent Street, Suite 103A, Waltham, MASSACHUSETTS 02453
Item 2.
(a)	Name of person filing: Kynam Capital Management, LP Kynam Capital Management GP, LLC Yue Tang
(b)	Address or principal business office or, if none, residence: 221 ELM ROAD PRINCETON, New Jersey 08540
(c)	Citizenship: Kynam Capital Management, LP - DELAWARE Kynam Capital Management GP, LLC - DELAWARE Yue Tang - UNITED STATES
(d)	Title of class of securities: Common Stock, $0.01 par value
(e)	CUSIP No.: 92790C104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 0
(b)	Percent of class: 5.7 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Kynam Capital Management, LP - 0 Kynam Capital Management GP, LLC - 0 Yue Tang - 0
	(ii) Shared power to vote or to direct the vote: Kynam Capital Management, LP - 6,453,877 Kynam Capital Management GP, LLC - 6,453,877 Yue Tang - 6,453,877
	(iii) Sole power to dispose or to direct the disposition of: Kynam Capital Management, LP - 0 Kynam Capital Management GP, LLC - 0 Yue Tang - 0
	(iv) Shared power to dispose or to direct the disposition of: Kynam Capital Management, LP - 6,453,877 Kynam Capital Management GP, LLC - 6,453,877 Yue Tang - 6,453,877
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Kynam Capital Management, LP

Signature:	Yue Tang
Name/Title:	Managing Member
Date:	08/14/2026

Kynam Capital Management GP, LLC

Signature:	Yue Tang
Name/Title:	Managing Member
Date:	08/14/2026

Yue Tang

Signature:	Yue Tang
Name/Title:	Self
Date:	08/14/2026